A panel of experts discusses key datasets in leukemia that were presented recently at the American Society of Clinical Oncology [ASCO] 2023 Annual Meeting and the European Hematology Association [EHA] 2023 Congress.
The Talk
Experts in hematologic oncology give an overview of first- and second-line MDS treatment options, and discuss updates from the ASH 2022 Annual Meeting.
Expert hematologist/oncologists review key datasets in leukemia presented at the ASH 2022 Annual Meeting.
Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.
Expert oncologists review key datasets in leukemia & lymphoma that were presented at the ASCO 2022 and EHA 2022 Annual Meetings.
Expert hematologist/oncologists come together to review key datasets in leukemia that were presented at the ASH 2021 Annual Meeting.
Sponsored in part by Takeda. Content independently developed by OncLive®
Virginia Kaklamani, MD, DSc, shares her excitement for an upcoming OncLive® "The TALK" program focusing on HER2-positive breast cancer updates from the SABCS 2021 Virtual Meeting.
Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky, MD, MS, review recent updates and data in breast cancer presented at the SABCS 2021 Virtual Meeting.
Experts in gastric cancers review recent updates and data in gastrointestinal cancers presented at the ESMO 2021 Virtual Meeting.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive.
Experts in breast oncology gather for a discussion on important datasets in breast cancer recently presented at the ESMO 2021 Virtual Meeting.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive.
Expert perspectives on trial designs, study populations, safety/efficacy results, and practical implications from the 2021 ASCO (American Society of Clinical Oncology) and EHA (The European Hematology Association).
Funding from Amgen Oncology and Takeda Oncology/Content Developed Independently by OncLive
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5